Could a once-daily pill protect older kidney transplant patients' thinking skills?
NCT ID NCT06751992
First seen Nov 18, 2025 · Last updated May 26, 2026 · Updated 24 times
Summary
This study tests whether switching to a once-daily anti-rejection drug (Envarsus XR) helps preserve memory and thinking in older kidney transplant patients compared to staying on a twice-daily drug (Prograf). About 92 participants who are at least one year post-transplant will take brain tests over several months. The goal is to see if the once-daily option leads to better brain function while still preventing organ rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLD AGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MGH Kidney Transplant Clinic
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.